跨性别男性个体的卵母细胞玻璃化冷冻结局
该回顾性队列研究于2017年1月至2021年6月在荷兰阿姆斯特丹联合医学院开展,连续纳入完成卵母细胞玻璃化冷冻治疗的跨性别男性个体,共24人签署知情同意,其中7人启动睾酮治疗者被建议在刺激前3个月停药。取卵后平均获卵20枚(标准差7),平均17枚(标准差6)可玻璃化冷冻。既往睾酮使用者与未使用睾酮者相比,除累积FSH剂量较低外无显著差异,治疗总体满意度高。
要点
- 既往睾酮使用与未使用睾酮的跨性别男性在卵巢刺激反应上无显著差异。
- 取卵后平均获卵20枚(标准差7),平均17枚(标准差6)可玻璃化冷冻。
- 29%的参与者认为激素注射是最费力的治疗环节,25%认为取卵术最费力。
核心结论
- 既往睾酮使用者与未使用睾酮的跨性别男性个体在卵母细胞玻璃化冷冻治疗中对卵巢刺激的反应无差异。
- 问卷显示激素注射是卵母细胞玻璃化冷冻治疗中最具负担的环节。
研究设计与样本
- 该研究为回顾性队列研究,于2017年1月至2021年6月在荷兰阿姆斯特丹联合医学院开展。
- 连续纳入完成卵母细胞玻璃化冷冻治疗的跨性别男性个体,共24人签署知情同意,其中7人启动睾酮治疗者被建议在刺激前3个月停药。
- 人口学特征与卵母细胞玻璃化冷冻治疗数据来自病历,治疗评价通过在线问卷收集。
主要发现
- 参与者中位年龄为22.3岁(四分位距21.1-26.0),平均体重指数为23.0 kg/m2(标准差3.2)。
- 卵巢超刺激后平均获卵20枚(标准差7),平均17枚(标准差6)可玻璃化冷冻。
- 既往睾酮使用者与未使用睾酮者相比,除累积FSH剂量较低外无显著差异。
- 参与者对卵母细胞玻璃化冷冻治疗的总体满意度高。
- 29%的参与者认为激素注射是最费力的治疗环节,25%认为取卵术最费力。
临床怎么用
- 作者认为该信息可用于改善性别敏感的生育咨询和生育治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What are the outcomes and experiences of oocyte vitrification treatment in trans masculine individuals (TMI) before and after testosterone use? DESIGN: This retrospective cohort study was conducted at the Amsterdam UMC in the Netherlands between January 2017 and June 2021. The TMI who had completed an oocyte vitrification treatment were consecutively approached for participation. Informed consent was provided by 24 individuals. Participants (n = 7) who initiated testosterone therapy were advised to stop 3 months before stimulation. Demographic characteristics and oocyte vitrification treatment data were retrieved from medical records. Evaluation of the treatment was collected via an online questionnaire. RESULTS: The median age of participants was 22.3 years (interquartile range 21.1-26.0) and mean body mass index was 23.0 kg/m2 (SD 3.2). After ovarian hyperstimulation, a mean of 20 oocytes (SD 7) were retrieved and a mean of 17 oocytes (SD 6) could be vitrified. Aside from a lower cumulative FSH dose, there were no significant differences between the prior testosterone users and testosterone naïve TMI. The overall satisfaction of oocyte vitrification treatment in participants was high. Hormone injections were considered the most strenuous part of treatment by 29% of participants, closely followed by oocyte retrieval (25%). CONCLUSIONS: No difference in response to ovarian stimulation was found for oocyte vitrification treatment between the prior testosterone users and testosterone naïve TMI. The questionnaire identified hormone injections as the most burdensome aspect of oocyte vitrification treatment. This information can be used to improve gender sensitive fertility counselling and fertility treatment strategies.
引用
- Asseler JD, Knieriem J, Huirne JA, et al. Outcomes of oocyte vitrification in trans masculine individuals. Reprod Biomed Online. 2023. PMID: 37095040. doi:10.1016/j.rbmo.2023.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。